Tyra Biosciences (TYRA) Common Equity (2020 - 2026)

Tyra Biosciences' Common Equity history runs 7 years deep, the most recent figure standing at $387.6 million for Q1 2026.

• Quarterly Common Equity rose 19.79% year-over-year to $387.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $387.6 million (up 19.79% YoY) and the FY2025 annual result came in at $259.2 million, down 24.47% from the prior year.
• Common Equity was $387.6 million for Q1 2026 at Tyra Biosciences, up from $259.2 million in the prior quarter.
• Across five years, Common Equity topped out at $389.9 million in Q1 2024 and bottomed at $204.3 million in Q4 2023.
• A 5-year average of $296.1 million and a median of $280.5 million in 2025 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2022 — Common Equity surged 1761.82% — and 2025, when it dropped 24.47%.
• Tyra Biosciences' Common Equity stood at $257.8 million in 2022, then retreated by 20.78% to $204.3 million in 2023, then surged by 68.0% to $343.2 million in 2024, then declined by 24.47% to $259.2 million in 2025, then soared by 49.54% to $387.6 million in 2026.
• Business Quant data shows TYRA's Common Equity at $387.6 million in Q1 2026, $259.2 million in Q4 2025, and $280.5 million in Q3 2025.